"The MRCG/HRB Joint Funding Scheme has enabled us in The Alzheimer Society of Ireland to fund large scale, high impact research, Not only maximising the resources we have available for research but enabling us to build links and establish relationships with leading researchers in the field of dementia. It's a hugely beneficial scheme; unique in supporting patient and patient organisations as key stakeholders in the research community while helping us to bridge the gap between research, policy and practice."
Emer Begley, Policy and Research Manager, The Alzheimer Society of Ireland
"Cystinosis Ireland is a small, all-volunteer charity. Our main aim is to raise money to fund research into cystinosis, an ultra-rare disease. We have participated in the Joint Funding Scheme since the start, and it has enabled us to be involved in funding research that would otherwise have been outside of our funding capabilities. Cystinosis is a life-threatening, chronic disease that has no cure. Our charity has funding priorities and areas of interest where we want to see research conducted. The nature of the Joint Funding Scheme, where the charity puts out the call for research, carries out all administration and peer review - in our case on a completely voluntary basis - and decides which projects go forward to the HRB review panel, means that those directly affected by cystinosis are part of that decision-making process. It means that the research conducted is the kind of research that will make a difference to lives - both in the short term and in the long term. The Joint Funding Scheme has helped put Cystinosis Ireland on the map in the cystinosis world and has put cystinosis on the world map for rare diseases."
Anne Marie O'Dowd, Director and Research Co-ordinator, Cystinosis Ireland
"Over the past ten years, the MRCG HRB joint funding scheme has been invaluable to the fundamental mission of Fighting Blindness which is to enable patient-led research. The scheme has helped us to identify and develop talented researchers working on treatments and cures for genetic and age-related forms of retinal degenerations. Many of our researchers have subsequently leveraged this scheme to secure funding for larger grants from other agencies. The scheme has provided a much need platform for patient-led research and we hope that this will become the template for other research grant agencies and funding streams in the future."
Maria Meehan, Research Manager, Fighting Blindness
"The Alpha One Foundation is a charity that is dedicated to increasing diagnosis, raising awareness and improving the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). The MRCG-HRB joint funding scheme has enabled us to co-fund a variety of research projects investigating the cause of the lung and liver disease in Alpha-1 patients. Recently, the scheme provided us with the opportunity to co-fund an exciting project with the US Alpha-1 Foundation investigating the reason for increased COPD risk in Z Alpha-1 carriers."
Catherine O'Connor, Chief Executive Officer, The Alpha One Foundation